文献速递胸部肿瘤

可切除临床N2非小细胞肺癌的最佳治疗策略:英国胸科学会肺癌专家咨询组更新

Resectable Clinical N2 Non-Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
PubMed 文献 · J Thorac Oncol · 2017-06-15

针对有临床证据显示同侧纵隔受累的可切除NSCLC,随机对照试验和Meta分析未能证明化疗加手术与化疗加放疗两种双模式策略孰优。一项三模式(化疗、放疗、手术)试验显示无进展生存优于化疗加放疗,但总生存无差异。尚无RCT专门比较单站N2与多站N2。肺癌团队应考虑三模式或双模式治疗,并主张所有患者均接受胸外科和肿瘤团队评估。

要点

  • RCT和Meta分析未能证明化疗加手术优于化疗加放疗。
  • 三模式较化疗加放疗改善无进展生存,但总生存无差异。
  • 无RCT专门比较单站N2与多站N2疾病。

核心结论

  • 对于适合的潜在可切除cN2 NSCLC患者,肺癌团队应考虑化疗、放疗和手术的三模式治疗,或化疗联合手术或放疗的双模式治疗。
  • 作者主张所有患者均应接受胸外科医生和肿瘤团队评估以讨论不同方案。

研究设计与样本

  • 本文为英国胸科学会肺癌专家咨询组更新的综述,汇总RCT和Meta分析证据。

主要发现

  • RCT和Meta分析未能证明化疗加手术优于化疗加放疗。
  • 一项三模式(化疗、放疗、手术)试验显示无进展生存优于化疗加放疗,但总生存无差异。
  • 尚无RCT专门研究单站N2与多站N2患者。
  • 该复杂且异质性患者群体的数据存在若干局限性。

临床怎么用

  • 对于适合的潜在可切除cN2 NSCLC患者,肺癌团队应考虑三模式治疗(化疗、放疗、手术)或双模式治疗(化疗联合手术或放疗)。
  • 作者主张所有患者均应接受胸外科医生和肿瘤团队评估以讨论这些不同方案。

局限性

  • 该复杂且异质性患者群体的数据存在若干局限性。
  • 尚无RCT专门研究单站N2与多站N2患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients and clinicians are faced with uncertainty as to the optimal treatment strategy for potentially resectable NSCLC in which there is clinical evidence of involvement of the ipsilateral mediastinum. Randomized controlled trials and meta-analyses have failed to demonstrate superiority of one bimodality strategy over another (chemotherapy plus surgery versus chemotherapy plus radiotherapy). One trial of trimodality treatment with chemotherapy, radiotherapy, and surgery demonstrated an improvement in progression-free, but not overall, survival versus chemotherapy and radiotherapy. There are a number of limitations to the data in this complex and heterogenous patient group. No randomized controlled trial has specifically studied patients with single-station N2 disease versus multistation N2 disease. When discussing treatment for fit patients with potentially resectable cN2 NSCLC, lung cancer teams should consider trimodality treatment with chemotherapy, radiotherapy, and surgery or bimodality treatment with chemotherapy and either surgery or radiotherapy. We advocate that all patients see both a thoracic surgeon and the oncology team to discuss these different approaches.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Evison M, Clive A, Castle L, et al. Resectable Clinical N2 Non-Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group. J Thorac Oncol. 2017. PMID: 28624466. doi:10.1016/j.jtho.2017.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。